Ana Ruiz Garcia, Pharm.D, Ph.D

Group Leader, Senior Principal Scientist I

Ana has over 18 years of industry drug development experience working with small and large molecules, mainly focused in the therapeutic areas of Oncology and Inflammation.  Ana has worked in the quantitative and regulatory aspects of many successful NDA/BLA submissions. Ana’s areas of expertise include characterization of drug myelosuppression, tumor growth inhibition and absorption models.

Recent publications by this scientist

Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer

July 19, 2021

Fostvedt LK, Shaik N, Martinelli G, Wagner AJ, Ruiz-Garcia A. Expert Rev Clin Pharmacol. 2021 Jul;14(7):927-935. doi: 10.1080/17512433.2021.1925538. Epub 2021 May 18.

View More

Pharmacometric Dose Optimization of Buprenorphine in Neonatal Opioid Withdrawal Syndrome

June 3, 2021

Eudy-Byrne, R., Zane, N., Adeniyi-Jones, S.C., Gastonguay, M.R., Ruiz-Garcia, A., Kushal, G. and Kraft, W.K. (2021). Clinical and Translational Science. Accepted Author Manuscript. https://doi.org/10.1111/cts.13074

View More

Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants

February 19, 2021

Chen J, Houk B, Pithavala YK, Ruiz-Garcia A. CPT Pharmacometrics Syst Pharmacol. 2021 Feb;10(2):148-160. doi: 10.1002/psp4.12585. Epub 2021 Feb 1.

View More